ELVN-001
Chronic Myeloid Leukemia (CML)
Phase 1bActive
Key Facts
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotech focused on developing precision small molecule kinase inhibitors to help cancer patients live longer and better lives. The company leverages a deep expertise in kinase biology and medicinal chemistry to create highly selective, combinable drugs that overcome resistance and address unmet needs. With a lead asset, ELVN-001, showing positive initial Phase 1b data in CML and a robust pipeline, Enliven is strategically positioned to advance novel therapies in competitive oncology markets.
View full company profileTherapeutic Areas
Other Chronic Myeloid Leukemia (CML) Drugs
| Drug | Company | Phase |
|---|---|---|
| XS003 (nilotinib) | Xspray Pharma | NDA Submitted |
| Scemblix® (asciminib) | Novartis | Approved / Lifecycle |
| TERN-701 | Terns Pharmaceuticals | Phase 3 |
| BCR-ABL1 (p210) Monitoring Assay | Sniper Medical Technologies | Commercial |